Ignite Creation Date:
2025-12-24 @ 12:34 PM
Ignite Modification Date:
2026-01-26 @ 5:07 PM
Study NCT ID:
NCT02122861
Status:
COMPLETED
Last Update Posted:
2019-03-06
First Post:
2014-04-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1
Sponsor:
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05-30
Start Date Type:
ACTUAL
Primary Completion Date:
2018-11-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-12-15
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-22
First Submit QC Date:
None
Study First Post Date:
2014-04-25
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-03-04
Last Update Post Date:
2019-03-06
Last Update Post Date Type:
ACTUAL